Form 4: Centessa Pharmaceuticals Acquisition Complete

Centessa Pharmaceuticals plc's acquisition by Eli Lilly and Company is finalized, with share options converted into cash and contingent value rights.

Summary

• Centessa Pharmaceuticals plc has been acquired by Eli Lilly and Company through a scheme of arrangement.
• The transaction, effective June 24, 2026, was executed by Eli Lilly's subsidiary, LDH XV Corporation.
• All outstanding ordinary shares of Centessa Pharmaceuticals were acquired.
• Share options, whether vested or unvested, were cancelled and converted into a right to receive cash and contingent value rights (CVRs).
• The cash component is the difference between $38.00 and the per-share exercise price of the option.
• Additionally, holders of share options will receive one non-transferable CVR per underlying ordinary share.
• These CVRs entitle holders to potential contingent payments of up to $9.00 per ordinary share.
• These payments are contingent upon the achievement of specified milestones outlined in a separate agreement.
• No share options were exercised prior to the effective time of the acquisition.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it confirms the completion of a previously announced acquisition, providing clarity for stakeholders. The cash and CVR structure offers a defined outcome for option holders, though the full value is contingent.

Positives

• Shareholders and option holders are set to receive cash payments and potential future payments through CVRs, providing a clear financial outcome.
• The acquisition by a major pharmaceutical company like Eli Lilly and Company suggests a positive valuation of Centessa's assets or pipeline.

Negatives

• Existing share options are cancelled, with no option for holders to retain their options in the new entity.
• The value of the CVRs is contingent on future milestone achievements, introducing uncertainty regarding the total payout.

Risks

• The realization of the full value of the contingent value rights (CVRs) is dependent on the achievement of specified milestones, which may not occur.
• There is a risk that applicable withholding taxes could reduce the net cash received by option holders.

Future Outlook

The future outlook for Centessa Pharmaceuticals plc is now integrated within Eli Lilly and Company. The primary future financial event for former option holders is the potential achievement of milestones tied to the contingent value rights, which could yield up to an additional $9.00 per share.

Management Comments

• Eli Lilly and Company, through its wholly owned subsidiary LDH XV Corporation, acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc by means of a scheme of arrangement.
• At the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a "CVR") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones.

Industry Context

StockSavvy.ai notes that this Form 4 filing details the completion of an acquisition, a common strategic move in the pharmaceutical and biotechnology sectors. Such acquisitions are often driven by the acquiring company's interest in the target's pipeline, technology, or market position. The structure involving cash and contingent value rights is a typical mechanism to bridge valuation gaps and incentivize the realization of future value from the acquired assets.

Comparison to Industry Standards

• Acquisition of smaller biotech/pharma companies by larger entities is a frequent occurrence, with recent examples including Pfizer's acquisition of Seagen and Bristol Myers Squibb's acquisition of Karuna Therapeutics.
• The use of contingent value rights (CVRs) is a standard practice in the industry to account for the inherent uncertainty in drug development and regulatory approval. For instance, the structure of CVRs in this transaction is comparable to those seen in other major pharmaceutical deals where future clinical trial success or regulatory approvals are key value drivers.
• The cash component of $38.00 per share, combined with potential CVRs, represents a valuation that would be benchmarked against similar-stage companies in the therapeutic areas Centessa was focused on at the time of the deal.

Stakeholder Impact

• Shareholders: The acquisition by Eli Lilly and Company signifies the end of Centessa Pharmaceuticals plc as an independent entity. Shareholders would have received cash and/or CVRs as per the terms of the acquisition.
• Option Holders: Existing share options have been cancelled and converted into a right to receive cash (based on exercise price) and contingent value rights, impacting their potential future equity participation.
• Employees: Employees holding share options will experience a change in their compensation structure, moving from potential equity gains to cash and contingent rights.
• Creditors: The acquisition by a larger entity like Eli Lilly may provide increased financial stability for Centessa's ongoing operations or obligations.

Next Steps

• Option holders will receive cash payments and contingent value rights.
• The achievement of specified milestones will determine the payout of the contingent value rights.

Key Dates

Keywords

Centessa Pharmaceuticals, Eli Lilly, Acquisition, Scheme of Arrangement, Share Options, Contingent Value Rights, CNTA, SEC Form 4, Merger